Extracellular Matrix (ECM) Therapy in Dayton, OH

CDC PLACES vs. J15: two files, not one brochure

Dayton is a city under 250k (137,644 Census). CDC PLACES (2023, crude) estimates 17.6% of adults in Dayton have diagnosed diabetes — 5.6 points above the U.S. 12% figure. Adult arthritis here is 28.4% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. Keep 361 tissue, autologous PRP, and skin substitutes on different tickets. We onboard against that split — then ship.

Cash PRP and Medicare CTPs in the same hallway

• CDC PLACES (2023, crude) estimates 17.6% of adults in Dayton have diagnosed diabetes — 5.6 points above the U.S. 12% figure. Adult arthritis here is 28.4% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. Separate 361 tissue, PRP, and CTP tickets before you market extracellular matrix therapy in Dayton. Mixing lanes is how recoupments start.
• Ohio includes counties CDC has described as part of the Diabetes Belt, so diabetic-complication volume is a standing planning input for wound-care and regenerative programs — not a seasonal talking point. Clinics asking for regenerative inventory still have to separate HCT/P 361 homologous-use products from unapproved “stem cell” claims (FDA 21 CFR 1271).
• PRP is autologous and not an HCT/P 361 allograft, but payers in J15 still expect diagnosis-driven documentation. A 1-minute spin does not replace a medically necessary indication or a procedure note.

Uninsured mix and Medicare CTPs in the same building

J15 reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Dayton is 17.6% or not. PLACES is planning data. The LCD is the claim.

Before the first extracellular matrix therapy shipment